Meropenem: evaluation of a new generation carbapenem

Blumer, Jeffrey L.

doi:10.1016/s0924-8579(96)00347-0

Cited by 49 publications

(27 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These isolates showed high resistance (100.0%) to β-lactams (OX, AMC, ampicillin); only the isolates from breeding mares group exhibited high resistance to OX and less resistance to AMC and ampicillin (10 µg). The sensibility to the carbapenem antibiotics meropenem, generally more potent against gram-negative bacteria, and imipenem, generally more potent against gram-positive bacteria [25] , was high in S. lentus and S. sciuri isolated from the three different groups of horses. All isolates of S. lentus in riding-horses showed resistance to cephalosporin (cefaclor, cefuroxime, cefprozil, and ceftriaxone), macrolides (erythromycin and MY) and tetracycline (tetracycline and doxycycline), whereas S. sciuri were resistant only to MY as well as S. lentus and S. sciuri isolated in harness racing-horses.…”

Section: Resultsmentioning

confidence: 94%

A comparative evaluation of methicillin-resistant staphylococci isolated from harness racing-horses, breeding mares and riding-horses in Italy

Mallardo

Nizza

Fiorito

et al. 2013

Asian Pacific Journal of Tropical Biomedicine

View full text Add to dashboard Cite

To investigate the prevalence of methicillin-resistant staphylococci (MRS) which is a potencial risk factor of transmission between animals and humans in different types of horses (harness racing-horses, breeding mares and riding-horses) and to compare the antimicrobial resistance of the isolates. A total of 191 healthy horses, housed at different locations of the Campania Region (Italy), were included in the study. Nasal swab samples were collected from each nostril of the horses. The mecA gene was detected by a nested PCR technique. Antibiotic susceptibility testing was performed for each isolate. MRS were isolated from nasal samples of 68/191 (35.6%; 95% CI: 28.9%-42.9%) healthy horses. All isolates were coagulasenegative with the exception of two coagulase-positive-MRS strains, identified as Staphylococcus aureus and Staphylococcus pseudintermedius, 2/83 (2.4%; 95% CI: 0.4%-9.2%). Interestingly, both coagulase-positive-MRS isolates were from harness racing-horses. These horses also presented a significant higher positivity for MRS (53.3%; 95% CI: 40.1%-66.1%) than the breeding mares and riding-horses groups. Antibiotic susceptibility testing resulted difference between isolates due to different origin except for an almost common high resistance to aminopenicillins, as ampicillin and amoxicillin. It can be concluded that harness racing-horses may act as a significant reservoir of MRS as compared to breeding mares and riding-horses

show abstract

Section: Resultsmentioning

confidence: 94%

A comparative evaluation of methicillin-resistant staphylococci isolated from harness racing-horses, breeding mares and riding-horses in Italy

Mallardo

Nizza

Fiorito

et al. 2013

Asian Pacific Journal of Tropical Biomedicine

View full text Add to dashboard Cite

show abstract

“…It has a very broad spectrum of antibacterial activity against the majority of gram-positive and Gram-negative pathogens [1]. Meropenem is more active in vitro than imipenem against Enterobacteriaceae and Pseudomonas aeruginosa, but less active against Gram-positive cocci [2]. This antibiotic is more stable to ring opening by human renal dehydropeptidase I (DHP-I) than imipenem and consequently does not require concomitant administration of a DHP-I inhibitor.…”

Section: Introductionmentioning

confidence: 99%

Microbiological assay for the determination of meropenem in pharmaceutical dosage form

Mendez

Weisheimer

Oppe

et al. 2005

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

“…Meropenem is a parenteral carbapenem antibacterial with properties appropriate for empirical therapy [reviewed by 1–3]. In most countries in which it is available, meropenem is licensed for use in the treatment of a broad range of infections, including lower respiratory tract, intra‐abdominal, obstetric/gynecological, urinary tract, skin/skin structure, meningitis, and also in cystic fibrosis and febrile neutropenia.…”

Section: Introductionmentioning

confidence: 99%

Meropenem: clinical response in relation to in vitro susceptibility

Drusano

Lode

Edwards

2000

Clinical Microbiology and Infection

View full text Add to dashboard Cite

The attractive in vitro profile of meropenem translates into good clinical efficacy. The National Committee for Clinical Laboratory Standards has now defined meropenem MIC breakpoints for nonfastidious aerobes or anaerobes as < or = 4 (susceptible), 8 (intermediate) and > or = 16 mg/L (resistant), respectively. The susceptibility breakpoint for Streptococcus spp. (excluding Streptococcus pneumoniae) is < or = 0.5 mg/L and, since meropenem is indicated for the treatment of meningitis, the susceptibility breakpoint for S. pneumoniae and Haemophilus influenzae is < or = 0.25 and < or = 0.5 mg/L, respectively. Meropenem monotherapy is therefore a valid option for the initial empirical treatment of a range of serious infections caused by single or multiple bacterial pathogens.

show abstract

Meropenem: evaluation of a new generation carbapenem

Cited by 49 publications

References 80 publications

A comparative evaluation of methicillin-resistant staphylococci isolated from harness racing-horses, breeding mares and riding-horses in Italy

A comparative evaluation of methicillin-resistant staphylococci isolated from harness racing-horses, breeding mares and riding-horses in Italy

Microbiological assay for the determination of meropenem in pharmaceutical dosage form

Meropenem: clinical response in relation to in vitro susceptibility

Contact Info

Product

Resources

About